Goldbug100 - Pharmalink International Limited – Results For the year ended 31 December 2010

12 April 2011 - Consolidated Financial Results for the Full Year Ended 31 December 2010

. Sales increased 60.00% to US$13,788,148 (2009 US$8,619,843)

. Net profit increased 155.70% to US$4,769,961 (2009) US$1,865,189)

. Net profit margin increased to 34.60% (2009 21.60%)

. Total assets increased 46.30% to US$12,507,627 (2009 US$8,551,381)

. Net asset value per share increased 29.50% to $US$6.31 (2009 US$4.87)

. Cash and deposits increased 44.60% to US$3,588,675 (2009 US$2,482,712) The Company has not debt

. Net profit per share was US$3.34 (2009 US$1.39) an increase of 156.90%

. Final dividend US$1.20 to be paid to shareholder on 31 May 2011 making a total for the year of $1.70

Sales increased in the USA Great Health Works (GHW) by 137.80% - Sales to European Distributors increased by 34.20% - Poland 1,176.25%

The shares are traded over the counter in Hong Kong., The highest price paid was US$22.95 and the lowest US$5.50 – the last trade US$22.95 13 December 2010

original shareholders acquired their holding in Pharmalink having been shareholders in Special Assets Limited (HK.B12179)

Company´s websites www.lyprinol.com and www.OmegaXL.com - Email skwok@sal.com.hk